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Early mortality outcomes of patients 
with fragility hip fracture and concurrent 
SARS- CoV-2 infection
a systeMatIC RevIew and Meta- analysIs
Aims
Hip fracture is a common condition of the older, frailer person. This population is also at risk 
from SARS- CoV-2 infection. It is important to understand the impact of coexistent hip frac-
ture and SARS- CoV-2 for informed decision- making at patient and service levels.
Methods
We undertook a systematic review and meta- analysis of observational studies of older (> 
60 years) people with fragility hip fractures and outcomes with and without SARS- CoV-2 
infection during the first wave of the COVID-19 pandemic. The primary outcome was early 
(30- day or in- hospital) mortality. Secondary outcomes included length of hospital stay and 
key clinical characteristics known to be associated with outcomes after hip fracture.
Results
A total of 14 cohort and five case series studies were included (692 SARS- CoV-2 positive, 
2,585 SARS- CoV-2 negative). SARS- CoV-2 infection was associated with an overall risk ratio 
(RR) for early mortality of 4.42 (95% confidence interval (CI) 3.42 to 5.82). Early mortality 
was 34% (95% CI 30% to 38%) and 9% (95% CI 8% to 10%) in the infected and noninfected 
groups respectively. Length of stay was increased in SARS- CoV-2 infected patients (mean 
difference (MD) 5.2 days (3.2 to 7.2)). Age (MD 1.6 years (0.3 to 2.9)); female sex (RR 0.83 
(95% CI 0.65 to 1.05)); admission from home (RR 0.51 (95% CI 0.26 to 1.00)); presence of 
dementia (RR 1.13 (95% CI 0.94 to 1.43)); and intracapsular fracture (RR 0.89 (95% CI 0.71 
to 1.11)) were not associated with SARS- CoV-2 infection. There were statistically, but not 
clinically, significantly greater Nottingham Hip Fracture Scores in infected compared with 
non- infected patients (MD 0.7 (0.4 to 0.9)).
Conclusion
SARS- CoV-2 infection is associated with worse outcomes after hip fracture. This is not ex-
plained by differences in patient characteristics. These data can be used to support informed 
decision- making and may help track the impact of widespread adoption of system- level and 
therapeutic changes in management of the COVID-19 pandemic.
Cite this article: Bone Jt Open 2021;2-5:314–322.
Keywords: Hip fracture, COvId-19, Mortality, Complications
Introduction
People who sustain hip fractures are also 
those likely to be at greatest risk from 
saRs- COv-2 infection due to their age 
and comorbidities.1 delays to hip fracture 
surgery are associated with an increased risk 
of death2,3 and the response to the COvId-19 
pandemic at organizational and clinical levels 
may have impacted our ability to provide 
timely surgery. Patients, families, clinicians, 
and service providers need objective data 
on the impact of COvId-19 to inform clinical 
and service delivery decision- making. the 
pandemic is likely to continue for the foresee-
able future and this study also aims to provide 
an insight into how hip fracture outcomes for 
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Fig. 1
summary of risk of bias assessments for all included studies, using the 
newcastle- Ottawa scale.10
people with and without confirmed saRs- COv-2 infec-
tion are being affected by the pandemic.
Our primary objective was to determine the associa-
tion between saRs- Cov-2 infection and mortality after 
hip fracture. secondary objectives were to describe the 
clinical characteristics of people with hip fracture with 
and without saRs- Cov-2 infection, and to investigate the 
association of infection with other outcomes.
Methods
we included any full text articles considering our spec-
ified population including randomized controlled trials, 
cohort studies, and case- control and case series studies. 
Previous systematic reviews were included, and the incor-
porated studies used if they met inclusion criteria. to be 
included, articles had to have been published in english 
or provide a link to an english translation. articles must 
also have been published between 1 december 2019 and 
23 november 2020, and searches were rerun at the time 
of final manuscript preparation.
studies were included for assessment of our primary 
outcome only if complete data on mortality were avail-
able and studies were only included for description of the 
‘hip fracture - saRs- Cov-2’ population if they contained 
adequate data on patient characteristics. we excluded 
individual case reports, conference abstracts, editorials, 
and opinion pieces. we excluded studies without an 
english translation, or those studies published outside 
the specified time frame.
population. we included adult patients (over 60 years 
of age) admitted with any fragility hip fracture, with a 
concurrent diagnosis of saRs- Cov-2 infection either at 
admission or during the index admission. we included 
patients with a fragility hip fracture as part of a polytrau-
ma, provided there was no associated head injury. we did 
not impose any limitations on sex, ethnicity, or nation-
ality. we also did not impose any limitations on comor-
bidities or functional status, including dementia or care 
home residency.
Exposure and comparisons. Patients were included 
whether saRs- Cov-2 infection was diagnosed pre- or 
post- admission. we included patients managed con-
servatively and with any form of surgical intervention. 
If an included study also contained a group of patients 
with fragility- related hip fractures without a diagnosis of 
saRs- Cov-2 (including patients who tested negative and 
those who were not tested) these patients were used as 
controls for comparisons (provided they were sufficiently 
matched for age and demographics). Contemporaneous 
and previous year controls were allowed.
Outcomes. Our primary outcome was early patient mor-
tality, combining hospital inpatient mortality and 30- day 
mortality as a single outcome. secondary outcomes in-
cluded a priori were: hospital length of stay (days); ad-
mission to intensive care unit (ICU) (proportion); wheth-
er surgical fixation was performed (proportion); time to 
surgical fixation (hours); reoperation rates (proportion); 
and discharge destination if reported (proportion). we 
also reported outcomes on respiratory and cardiovascu-
lar complications including but not limited to: supple-
mental oxygen therapy requirement; respiratory arrest; 
myocardial infarction; and venous thromboembolism.
Search strategy. this systematic review was conducted 
and reported in accordance with Preferred Reporting 
Items for systematic Reviews and Meta- analyses guide-
lines4 and registered on PROsPeRO. Using the Healthcare 
database advanced search (property of national Institute 
for Health and Care excellence (nICe)), we conducted a 
Boolean search on PubMed (1946 to 2020), MedlIne 
(1946 to 2020), embase (1974 to 2020), and CInaHl 
(1981 to 2020) for various terms referring to "COvId-19" 
and "hip fracture". exploded Medical subject Headings 
terms were used on MedlIne and embase. to increase 
our scope, a separate search was also conducted us-
ing sCOPUs (1966 to 2020), Google scholar, and the 
Cochrane library. Backwards and forwards citation 
searches were also conducted using the references of in-
cluded studies.
Data collection and analysis. two reviewers (Ha, eM) in-
dependently assessed the eligibility of articles based on 
our inclusion criteria by screening titles and abstracts. 
selected articles were then subjected to a full- text read 
and excluded based on our criteria. disagreements were 
resolved via discussion with an independent third re-
viewer (IKM). data were recorded in comma- separated 
value data tables. all study data were double checked 
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Fig. 2
Risk of bias for individual studies, using the newcastle- Ottawa scale.10
by at least two of the investigators. In addition to par-
ticipant outcomes, data were extracted on the number 
of saRs- Cov-2 positive hip fracture patients, the number 
saRs- Cov-2 negative hip fracture control patients, and 
patient characteristics (where available). this included 
sex, age, presence of dementia, comorbidities, source 
of admission, nottingham Hip Fracture score (nHFs),5–7 
Charlson Comorbidity Index (CCI),5 and american society 
of anesthesiologists (asa) physical status.8 standard de-
viations (sds) were estimated from interquartile rang-
es (IQRs) using the approach recommended by wan et 
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Fig. 3
Funnel plot of included studies for risk of mortality associated with saRs- 
Cov-2 and hip fracture.
al.9 Risk of bias assessments were performed using the 
newcastle- Ottawa scale.10
Statistical analysis. analysis and data presentation were 
performed using R and the meta package (R Foundation 
for statistical Computing, austria). where appropriate, 
meta- analysis was performed using Mantel- Haenszel 
risk ratios (RRs) with 95% confidence intervals (CIs). a 
dersimonian random effects model was used as we an-
ticipated high levels of heterogeneity. we estimated pub-
lication bias for the primary outcome using funnel plots. 
sensitivity analyses are reported with data restricted to 
larger studies (≥ 30 included participants in the non- 
saRs- Cov-2 group or ≥ ten deaths in the saRs- Cov-2 
group).
Results
a total of 16 studies describing 14 cohorts (564 
saRs- Cov-2 positive, 22,585 saRs- Cov-2 negative) were 
included.11–26 Of these, 11 studies originated from the 
UK,11,13–15,17,20–22,24–26 three from the Usa,12,16,23 and one 
each from Italy18 and spain.19 the report from Clement 
et al24 is an expansion of the data reported by Hall et al.14 
Only mortality data from Clement et al24 are included; 
all other data are from Hall et al.14 the reports from egol 
et al12 and Konda et al23 describing the same cohort and 
data have been combined. In addition, we encountered 
five case series articles.27–31
all observational studies reported similar patient 
demographics, with the exception of the patient popu-
lation for Kayani et al,15 which contained younger, fitter 
patients with a greater proportion of intracapsular frac-
tures. analyses were repeated with this study excluded. 
Of the observational studies, 11 directly compared 
positive and negative saRs- Cov-2 cases11–16,18–20,23–26 
while three studies compared positive cases during the 
pandemic period with matched patients from 2019 or the 
pre- pandemic period.17,21,22
two studies did not report the diagnosis method of 
COvId-19.11,21 all other studies reported using poly-
merase chain reaction (PCR) but no details of cycle count 
thresholds were provided. Most studies gave little (e.g. 
‘clinically indicated’) or no detail on the indications 
for, or symptoms in, those tested.11–14,17–26 Kayani et al15 
reported that 73 of 82 saRs- Cov-2 cases were symptom-
atic; 54/82 had respiratory symptoms or fever. leBrun et 
al16 reported that 4/9 saRs- Cov-2 cases were hypoxic. 
Hall et al14 reported that seven of 27 saRs- Cov-2 posi-
tive patients had symptoms ‘suggestive of COvId-19 at 
admission’, and the remainder became swab positive 
(presumably based on testing after clinical suspicion) 
later during admission. the proportions of the cohort 
study populations tested was reported in seven studies 
(median 0.56 (IQR 0.44 to 0.7)).11,16,17,19,21,22,25 there was 
one recently published systematic review that identified 
six studies up to July 2020.32
Risk of bias assessment. the observational cohort studies 
were generally at low risk of bias for the primary outcome 
(Figures 1 and 2) and length of stay and patient character-
istics where reported. the case series were at higher risk 
of bias for representativeness of the cohort and a lack of 
control for confounding factors. there was no evidence 
of publication bias for mortality outcomes assessed by 
funnel plot (Figure 3).
Early mortality. a total of 14 cohorts from 16 studies 
were included reporting early mortality. ten reported 30- 
day mortality. Of the others, mortality was reported as 
inpatient in one,16 a minimum of ten days (mean 15 days) 
in another,19 and unclear in two studies.18,21 ten cohorts 
(442 patients) were from the UK, two from the Usa (40 
patients), and one each from spain (23 patients) and Italy 
(32 patients). Four case series reported early mortality at 
seven days,27 14 to 39 days,30 30 days,29 and unclear in 
one.31 the overall RR for early mortality was 4.42 (95% CI 
3.42 to 5.82) (Figure 4). this result was qualitatively un-
affected by inclusion of larger studies only (RR 5.4 (95% 
CI 3.4 to 8.58) or limiting outcomes to 30- day mortality 
(RR 3.91 (95% CI 3.01 to 5.09). the absolute risk of ear-
ly mortality was 34% (95% CI 30% to 38%) for patients 
with confirmed saRs- Cov-2 compared with 9% (8% to 
10%) in contemporaneous patients without confirmed 
infection (Figure 5).
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Fig. 4
Risk ratio for early mortality associated with saRs- Cov-2 infection in older people with fragility hip fracture. CI, confidence interval.
six studies reported mortality outcomes for nonin-
fected patients during the pandemic and equivalent 
cohorts from 2019.11,12,17,18,21,22 the relative risk of early 
mortality in the saRs- Cov-2 negative 2020 cohorts (n = 
458) compared to 2019 (n = 572) was 1.09 (95% CI 0.69 
to 1.73).
two studies reported data for patients with a diagnosis 
of saRs- Cov-2 at or shortly after admission compared 
with those with a later (≥ seven days) diagnosis.14,29 
Mortality at 30 days was not significantly different in 
either study (RR 1.18 (0.62 to 2.22)29 and 3/6 vs 6/21).14
Characteristics of patients with and without confirmed 
SARS-CoV-2 infection. eight cohorts11,12,14–16,20,23,25,26 re-
ported data for age. Patients with confirmed saRs- Cov-2 
infection were significantly older than those without 
(mean difference 1.6 years (0.3 to 2.9)) (Figure 6).
nine cohorts11–16,20,23,25,26 reported data on sex distri-
butions (1,533 female, 789 male). Female sex was not 
associated with confirmed saRs- Cov-2 diagnosis (RR 
0.83 (95% CI 0.65 to 1.05)). exclusion of smaller studies 
did not change this lack of association (RR 1.04 (0.65 to 
1.66)).
seven studies13–16,20,25,26 reported data on source of 
admission distributions (1,386 home, 428 not home). 
admission from home was not associated with confirmed 
saRs- Cov-2 diagnosis (RR 0.51 (95% CI 0.26 to 1.00)). 
exclusion of the study by Kayani et al15 resulted in a 
significant association between source of admission and 
saRs- Cov-2 diagnosis (RR 0.74 (95% CI 0.58 to 0.93)). 
exclusion of smaller studies did not change this lack of 
association (RR 0.43 (95% CI 0.16 to 1.17)).
six cohorts12,14–16,23,25,26 reported data on presence 
of dementia (or cognitive dysfunction). a diagnosis of 
dementia was not associated with confirmed saRs- Cov-2 
diagnosis (RR 1.13 (95% CI 0.94 to 1.43)). exclusion of 
smaller studies did not change this lack of association (RR 
1.14 (95% CI 0.92 to 1.41)).
data for global markers of frailty or comorbidity 
were reported adequately by eight studies: nHFs by 
five,11,14,20,25,26 CCI by two,12,13,23 and asa by three.15,25,26 
nHFs were greater in patients with saRs- Cov-2 infec-
tion (Md 0.7 (0.4 to 0.9)) (Figure 7). CCI scores were not 
significantly different between patients with and without 
saRs- Cov-2 infection in the studies that reported them. 
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Fig. 5
absolute risk for early mortality associated with saRs- Cov-2 infection in older people with fragility hip fracture. CI, confidence interval.
Mean asa grades were not different between groups 
(Md 0.2 (-0.1 to 0.4)).
the distribution of fracture types was reported from 
nine cohorts11–16,20,23,25,26 and was not associated with risk 
of infection (intracapsular fracture RR 0.89 (95% CI 0.71 
to 1.11)).
Risk factors for mortality in patients with confirmed 
SARS-CoV-2 infection. Four studies provided data on risk 
factors associated with mortality in the presence of con-
firmed saRs- Cov-2 infection.15,25,28,29 Multiple comorbidi-
ties were identified as a significant risk factor in two stud-
ies,15,25 and increasing age was identified as a risk factor 
only in one study.28 Male sex was associated with mortal-
ity by two studies25 but not the other two.15,29
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Fig. 6
Mean difference in age between saRs- Cov-2 positive and negative patients with hip fracture. CI, confidence interval.
Fig. 7
Mean difference in nottingham Hip Fracture score between saRs- Cov-2 positive and negative patients with hip fracture. CI, confidence interval.
Causes of death were generally not reported. arafa 
et al11 described seven out of seven saRs- Cov-2 posi-
tive deaths as COvId-19 pneumonitis; Konda et al23 and 
Fadulelmola et al13 found that seven out of 11 and seven 
out of ten deaths were associated with pneumonia or 
COvId-19 pneumonia respectively; and thrakar et al22 
and ward et al26 reported four out of seven and 14 out of 
17 with COvId-19 as a contributory cause, respectively.
details of included and excluded studies and all 
secondary analyses are available from the corresponding 
author (supplementary Material).
Discussion
around one in three older people with hip fracture 
and infection with saRs- Cov-2 died within 30 days at 
the time of the ‘first wave’ of the pandemic, compared 
with around one in ten without known infection. this 
was despite clinically minimal differences in important 
characteristics.
all of the included studies were of good quality as 
assessed by the newcastle- Ottawa ratings. almost all of 
the data reported are from ‘western’ healthcare systems, 
so we cannot draw conclusions about other systems or 
populations. the association between saRs- Cov-2 infec-
tion and outcome is robust to the exclusion of smaller 
studies. all of the studies reported data from around 
the time of peak infection in their respective country. 
there is a risk of confirmation bias as sicker patients 
were more likely to be tested, particularly in the early 
phase of the pandemic. However, qualitatively, the high 
30- day mortality appears consistent regardless of testing 
strategy. where reported, most patients with positive tests 
had symptoms, or the testing was ‘clinically indicated’. 
we suggest that as second and third waves of COvId-19 
appear around the world, it is important that clinicians 
collect and report data on hip fracture outcomes.
It is unlikely that false positive results were a partic-
ular issue given that testing was clinically driven, rather 
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than screening for all. there will be number of unknown 
saRs- Cov-2 infections either due to false negative test 
results, or lack of any testing. However, the mortality in 
the ‘negative’ groups is broadly the same as previous 
years, suggesting either that the rate of saRs- Cov-2 infec-
tion was low or that asymptomatic saRs- Cov-2 infection 
is not associated with marked increases in mortality.
we suggest that these data are important for several 
reasons. First, they provide information to support clin-
ical decision- making and communication. at the start 
of the pandemic, nHs guidance on management of hip 
fractures stated that “most people with coronavirus will 
survive, even those with frailty.”33 this, and other similar 
statements, now have data to support them. Clinicians 
and those responsible for service delivery can use these 
data to continue to provide patient- centred hip fracture 
services. saRs- Cov-2 is not a contraindication to surgery 
after hip fracture, even if the outcomes are worse. Honest 
communication with patients and their loved ones 
remains as important as ever.
second, they provide indirect evidence of the additional 
impact of symptomatic saRs- Cov-2 infection. there have 
been questions asked about whether people are dying 
with, rather than of, COvId-19. we would argue that the 
three- to four- fold increase in 30- day mortality between 
patients with and without saRs- Cov-2 infection during 
the first wave, in the absence of clinically important 
difference in other predictors of outcome, is strongly 
supportive of the causative role of infection in death. 
the difference in nHFs, while statistically significant, is 
not sufficient to explain the increased mortality. where 
reported, the presenting symptoms and cause of death 
are clearly ascribed to complications from COvId-19.
third, most of the data reported here, though not 
all, have used the england, wales, and northern Ireland 
(national Hip Fracture database) or scottish (scottish 
Hip Fracture audit) databases as existing frameworks 
for rapid, robust data collection. without the existence 
of these continuous data collection tools, it is unlikely 
that such high- quality data would have been available so 
quickly.
Finally, the comparative data between patient 
outcomes during the pandemic and in comparable 
cohorts from previous years would suggest that clini-
cians and services have succeeded in protecting the care 
of older patients with hip fracture despite the pandemic 
pressures.
However, this study also raises questions. the impact 
of nosocomial saRs- Cov-2 infection is not clear. Only two 
studies reported these data, and even here the distinction 
between hospital- acquired and initially undiagnosed is 
not clear.14,29 the data from the International Multicentre 
Project auditing COvId-19 in trauma & Orthopaedics 
(IMPaCt) studies suggest that outcomes are similar 
regardless of time of diagnosis. the current data do not 
allow distinction between an association of hospital- 
acquired COvId-19 with those at higher risk of adverse 
outcome, versus hospital- acquired infection causing a 
worse outcome. the clinically driven nature of testing 
would suggest that later- onset COvId-19 was not simply 
an asymptomatic association, though unfortunately 
symptoms at postoperative onset were poorly described. 
It is not known whether outcomes will be different in 
second or third waves. widespread vaccination is hoped 
to reduce the incidence and severity of COvId-19. Patients 
presenting with hip fracture and saRs- Cov-2 infection in 
the first wave may have a different risk profile to those 
presenting later and hospitals are hopefully better able to 
reduce the risk of nosocomial infection.
Mortality after hip fracture is significantly worse in the 
presence of saRs- Cov-2 infection, but the majority of 
patients will survive to 30 days. these outcomes after hip 
fracture are not readily explained by differences in patient 
characteristics. Future studies should ideally report the 
symptoms and signs present when a laboratory diagnosis 
is made, alongside the timing, to better inform under-
standing of the impact of infection in this vulnerable 
group. More data are needed to understand, and ideally 
prevent, the impact of hospital- acquired saRs- Cov-2 in 
this vulnerable patient population.
Twitter
Follow E. A. Moppett @EllieMoppett
Follow I. K. Moppett @iainmoppett
Supplementary material
  Figures for supplementary analyses not reported 
in main paper.
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